SCHEMBL336805

SCHEMBL336805

O=C([O-])CC(O)(C(=O)[O-])C(O)C(=O)[O-].O=C([O-])CC(O)(C(=O)[O-])C(O)C(=O)[O-].[Ca+2].[Ca+2].[Ca+2]

nearest known ligand 0.43

Known targets — ChEMBL curated mechanism

GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHMGCRMMP1MMP13MMP7MMP8PTGS1PTGS2ileSpolrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CA4 P22748 3/20 0.43
CPT2 P23786 1/20 0.33
ACLY P53396 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18124081 0.98 CA4 (0.41) CA4CPT2ACLY
Potassium Ion SCHEMBL1767658 0.98 CA4 (0.41) CA4CPT2ACLY
Potassium Ion SCHEMBL29489145 0.98 CA4 (0.41) CA4CPT2ACLY
SCHEMBL1767657 0.98 CA4 (0.41) CA4CPT2ACLY
SCHEMBL31473016 0.96 CA4 (0.48) CA4CPT2ACLY
SCHEMBL1460547 0.96 CA4 (0.43) CA4CPT2ACLY
Zinc Ion SCHEMBL2315207 0.96 CA4 (0.43) CA4CPT2ACLY
SCHEMBL965645 0.96 CA4 (0.48) CA4CPT2ACLY
SCHEMBL990294 0.96 CA4 (0.43) CA4CPT2ACLY
Potassium Ion SCHEMBL337213 0.96 CA4 (0.43) CA4CPT2ACLY

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118956849-A Preparation method of immobilized lipase and application of immobilized lipase in catalytic synthesis of glyceride 广东药科大学 2024-11-15 CN claimed
CN-116549427-A New use of hydroxycitric acid for treating cholelithiasis and cholecystitis induced by cholelithiasis 时珍本草生物科技(中山)有限公司 2023-08-08 CN claimed
CN-110363765-B Osteoporosis parameter automatic measurement method based on CT image 江苏天影医疗科技有限公司 2023-04-18 CN claimed
CN-108047029-A A kind of preparation method of the extraction purification hydroxycitric acid from Garcinia Cambogia 南京慧博生物科技有限公司 2018-05-18 CN claimed
CN-104844447-B Method for preparing high-purity hydroxycitric acid with garcinia cambogia as raw material 义乌章舸生物工程有限公司 2017-01-18 CN claimed
CN-104844447-A Method for preparing high-purity hydroxycitric acid with garcinia cambogia as raw material JIANGR BIO TECHNOLOGY CO LTD 2015-08-19 CN claimed
CN-104725218-A Method for extracting and purifying hydroxycitric acid from garcinia cambogia LI YUSHAN 2015-06-24 CN claimed
US-7858128-B2 Hydroxycitric acid compositions, pharmaceutical and dietary supplements and food products made therefrom, and methods for their use in reducing body weight INTERHEALTH NUTRACEUTICALS, INC. (US) 2010-12-28 US claimed
US-20090155391-A1 HYDROXYCITRIC ACID SALT COMPOSITION AND METHOD OF USE FOR REDUCING BODY WEIGHT UNIBAR CORPORATION (US) 2009-06-18 US claimed
US-7507421-B2 Hydroxycitric acid salt composition and method of making UNIBAR CORPORATION (US) 2009-03-24 US claimed
WO-2005085164-A1 NOVEL TRIPLE MINERAL SALTS OF (-)-HYDROXYCITRIC ACID AND PROCESSES FOR PREPARING THE SAME GOKARAJU GANGA RAJU (IN) 2005-09-15 WO claimed
US-20040259937-A1 Hydroxycitric acid complex metal salts, composition, and methods INDFRAG LIMITED (IN) 2004-12-23 US claimed
US-20040219124-A1 Cosmetic and Pharmaceutical Masks Based on Ion-Pair Delivery System GUPTA SHYAM K (US) 2004-11-04 US claimed
WO-2003092730-A1 HYDROXYCITRIC ACID SALT COMPOSITION AND METHOD OF MAKING UNIBAR CORPORATION (US) 2003-11-13 WO claimed
US-20030207942-A1 Hydroxycitric acid salt composition and method of making UNIBAR CORPORATION (US) 2003-11-06 US claimed
EP-0787489-B1 Composition containing propionyl-L-carnitine and hydroxycitric acid or pantothenic acid SIGMA TAU HEALTHSCIENCE SPA (IT) 2003-07-30 EP claimed
US-20010011081-A1 Pharmaceutical composition comprising L- carnitine or alkanoyl L-carnitine for the prevention and treatment of diseases brought about by lipid metabolism disorders SIGMA-TAU INDUSTRIE PARMACEUTICHE RIUNITE S.P.A. (IT) 2001-08-02 US claimed
US-6217898-B1 ANTICHOLESTEROL AGENTS SIGMA-TAU HEALTHSCIENCE S.P.A. (IT) 2001-04-17 US claimed
WO-2000015051-A1 HYDROXYCITRIC ACID COMPOSITIONS INTERHEALTH NUTRACEUTICALS, INC. (US) 2000-03-23 WO claimed
EP-0787489-A2 Composition containing L-carnitine or alkanoyl-L-carnitine and hydroxycitric acid or pantothenic acid Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) 1997-08-06 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090155391-A1 HYDROXYCITRIC ACID SALT COMPOSITION AND METHOD OF USE FOR REDUCING BODY WEIGHT HCAR1, HCAR2, HCAR3 CA4 134/4885CPT2 194/4885ACLY 376/4885
US-20030207942-A1 Hydroxycitric acid salt composition and method of making HCAR1, HCAR2, HAAO CA4 153/4885CPT2 845/4885ACLY 478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.